Olema Pharmaceuticals Files 8-K

Ticker: OLMA · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1750284

Olema Pharmaceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyOlema Pharmaceuticals, INC. (OLMA)
Form Type8-K
Filed DateMar 5, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, SEC Filing, Regulation FD

TL;DR

Olema Pharma filed a routine 8-K, no major news.

AI Summary

Olema Pharmaceuticals, Inc. filed an 8-K on March 5, 2025, to report information under Regulation FD and to file financial statements and exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates Olema Pharmaceuticals is fulfilling its regular reporting obligations with the SEC, which is standard for publicly traded companies.

Risk Assessment

Risk Level: low — This filing is a routine disclosure and does not contain any new material information that would impact the company's risk profile.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Olema Pharmaceuticals?

The 8-K filing is to report information under Regulation FD Disclosure and to file Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported was on March 05, 2025.

What is Olema Pharmaceuticals' principal executive office address?

The principal executive offices are located at 780 Brannan Street, San Francisco, California 94103.

What is Olema Pharmaceuticals' telephone number?

The company's telephone number is (415) 651-3316.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 regarding Olema Pharmaceuticals, Inc. (OLMA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing